STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Van Herk Acquired 1.07M PRQR Shares for $2.40M; 12.6% Ownership Reported

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

Van Herk group now holds a 12.6% stake in ProQR Therapeutics N.V. The Schedule 13D/A reports that Van Herk Investments B.V. and affiliated entities beneficially own 13,274,690 ordinary shares out of 105,344,052 outstanding shares as of June 30, 2025. From August 20, 2025 to September 3, 2025, Van Herk Investments B.V. purchased 1,072,500 ordinary shares in open market transactions for an aggregate net amount of $2,401,687.56, funded from its general working capital. The filing states the shares were acquired for investment purposes and that the Reporting Persons will continue to review their investment and may, depending on circumstances, communicate with management or the board, make proposals regarding capitalization or board composition, buy or sell shares, or use hedging or derivative transactions.

Positive

  • Increased, material stake: Reporting Persons beneficially own 13,274,690 shares representing 12.6% of outstanding ordinary shares.
  • Transparent disclosure of purchases: VHI acquired 1,072,500 shares in the open market for an aggregate net amount of $2,401,687.56.

Negative

  • Potential for governance or strategic changes: Reporting Persons reserve the right to engage with management, propose board or capitalization changes, or pursue business combinations.
  • Introduces uncertainty: The broad set of possible future actions (purchases, sales, hedging, proposals) could lead to volatility or shifts in shareholder dynamics.

Insights

TL;DR A sizable 12.6% stake was accumulated via open-market purchases, increasing Van Herk's influence over PRQR equity.

The disclosed 13,274,690-share position represents a material minority stake for ProQR and was increased by 1,072,500 shares acquired for $2.40 million over the two-week period ending September 3, 2025. For investors, a 12.6% stake can meaningfully affect stock liquidity and could signal strategic interest from a concentrated shareholder. The filing explicitly preserves a wide range of potential future actions by the Reporting Persons, from engagement with management to proposals on board structure or capitalization and use of derivatives, which introduces governance and strategic variability for the company. This is a notable ownership disclosure that merits monitoring for subsequent filings or communications.

TL;DR The group disclaims beneficial ownership for many entities but retains coordinated control; potential for governance engagement exists.

The Schedule 13D/A identifies a structured ownership chain among Dutch entities and an individual, with multiple entities disclaiming beneficial ownership while reporting shared voting and dispositive power. The filing explicitly permits future engagement with management or proposals regarding board composition and capitalization. While such language is standard in Schedule 13D amendments, it notifies stakeholders that the Reporting Persons reserve the right to pursue governance initiatives, creating potential for constructive dialogue or activist-style proposals. Absent any announced proposals, the immediate governance impact is informational rather than actionable.






If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D




Comment for Type of Reporting Person:
* Based on 105,344,052 ordinary shares, nominal value Euro 0.04 per share, of ProQR Therapeutics N.V. (the "Issuer") issued and outstanding as of June 30, 2025, as reported in the Issuer's Form 6-K filed with the SEC on August 7, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
* Based on 105,344,052 ordinary shares, nominal value Euro 0.04 per share, of the Issuer issued and outstanding as of June 30, 2025, as reported in the Issuer's Form 6-K filed with the SEC on August 7, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
* Based on 105,344,052 ordinary shares, nominal value Euro 0.04 per share, of the Issuer issued and outstanding as of June 30, 2025, as reported in the Issuer's Form 6-K filed with the SEC on August 7, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
* Based on 105,344,052 ordinary shares, nominal value Euro 0.04 per share, of the Issuer issued and outstanding as of June 30, 2025, as reported in the Issuer's Form 6-K filed with the SEC on August 7, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
* Based on 105,344,052 ordinary shares, nominal value Euro 0.04 per share, of the Issuer issued and outstanding as of June 30, 2025, as reported in the Issuer's Form 6-K filed with the SEC on August 7, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
* Based on 105,344,052 ordinary shares, nominal value Euro 0.04 per share, of the Issuer issued and outstanding as of June 30, 2025, as reported in the Issuer's Form 6-K filed with the SEC on August 7, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
* Based on 105,344,052 ordinary shares, nominal value Euro 0.04 per share, of the Issuer issued and outstanding as of June 30, 2025, as reported in the Issuer's Form 6-K filed with the SEC on August 7, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
* Based on 105,344,052 ordinary shares, nominal value Euro 0.04 per share, of the Issuer issued and outstanding as of June 30, 2025, as reported in the Issuer's Form 6-K filed with the SEC on August 7, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
* Based on 105,344,052 ordinary shares, nominal value Euro 0.04 per share, of the Issuer issued and outstanding as of June 30, 2025, as reported in the Issuer's Form 6-K filed with the SEC on August 7, 2025.


SCHEDULE 13D


Van Herk Investments B.V.
Signature:/s/ Erik G.A. Esveld
Name/Title:Erik G.A. Esveld/Attorney-In-Fact*
Date:09/04/2025
Van Herk Investments THI B.V.
Signature:/s/ Erik G.A. Esveld
Name/Title:Erik G.A. Esveld/Attorney-In-Fact*
Date:09/04/2025
Van Herk Private Equity Investments B.V.
Signature:/s/ Erik G.A. Esveld
Name/Title:Erik G.A. Esveld/Attorney-In-Fact*
Date:09/04/2025
Stichting Administratiekantoor Penulata
Signature:/s/ Erik G.A. Esveld
Name/Title:Erik G.A. Esveld/Attorney-In-Fact*
Date:09/04/2025
Van Herk Management Services B.V.
Signature:/s/ Erik G.A. Esveld
Name/Title:Erik G.A. Esveld/Attorney-In-Fact*
Date:09/04/2025
Onroerend Goed Beheer- en Beleggingsmaatschappij A. van Herk B.V.
Signature:/s/ Erik G.A. Esveld
Name/Title:Erik G.A. Esveld/Attorney-In-Fact*
Date:09/04/2025
A. van Herk Holding B.V.
Signature:/s/ Erik G.A. Esveld
Name/Title:Erik G.A. Esveld/Attorney-In-Fact*
Date:09/04/2025
Stichting Administratiekantoor Abchrys
Signature:/s/ Erik G.A. Esveld
Name/Title:Erik G.A. Esveld/Attorney-In-Fact*
Date:09/04/2025
Adrianus van Herk
Signature:/s/ Erik G.A. Esveld
Name/Title:Erik G.A. Esveld/Attorney-In-Fact*
Date:09/04/2025
Comments accompanying signature:
* Pursuant to a Power of Attorney, dated as of September 16, 2019, by and among the Reporting Persons.

FAQ

How many ProQR (PRQR) shares does the Van Herk group beneficially own?

The Reporting Persons beneficially own 13,274,690 ordinary shares, representing 12.6% of the class based on 105,344,052 shares outstanding as of June 30, 2025.

When and how many shares did Van Herk Investments B.V. recently acquire in PRQR?

From August 20, 2025 to September 3, 2025, Van Herk Investments B.V. acquired 1,072,500 ordinary shares in open market transactions.

What was the aggregate cost of the recent Van Herk purchases of PRQR shares?

The aggregate net amount paid for the 1,072,500 shares was $2,401,687.56, funded from the general working capital of Van Herk Investments B.V.

What does the Schedule 13D/A say about Van Herk's intentions for its PRQR stake?

The filing states the shares were acquired for investment purposes and that the Reporting Persons may review their investment and potentially engage with management, propose changes to board or capitalization, buy or sell shares, or use hedging/derivative transactions.

Do the Reporting Persons claim coordinated ownership or separate ownership?

The filing describes an ownership chain among affiliated entities and indicates shared voting and dispositive power over the reported shares, while several entities disclaim beneficial ownership.
Proqr Therapeuti

NASDAQ:PRQR

PRQR Rankings

PRQR Latest News

PRQR Latest SEC Filings

PRQR Stock Data

220.17M
86.34M
18.04%
51.67%
0.52%
Biotechnology
Healthcare
Link
Netherlands
Leiden